DDInter119 DDInter1802
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Ticagrelor {u} (Compound) treats {v} (Disease) coronary artery disease
Ticagrelor {u} (Compound) binds {v} (Gene) ABCB1
Ticagrelor {u} (Compound) is included by {v} (Pharmacologic Class) Phenylalanine Hydroxylase Activators
Ticagrelor {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Ticagrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Ticagrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nifedipine
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lepirudin
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Indinavir
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Relugolix
Ticagrelor (Compound) treats coronary artery disease (Disease)
Ticagrelor (Compound) binds ABCB1 (Gene)
Ticagrelor (Compound) is included by Phenylalanine Hydroxylase Activators (Pharmacologic Class)
Ticagrelor (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect)
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Clove
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Nifedipine
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Ticagrelor may lead to a major life threatening interaction when taken with Indinavir
Ticagrelor may lead to a major life threatening interaction when taken with Relugolix